Nine months from approval to market—now comes the real test
In the long arc of biotech development, where years of research often end in regulatory silence, Precigen arrived at a different moment in May 2026 — nine months into the commercial life of PAPZIMEOS, its first approved therapeutic. The drug, cleared by the FDA in August 2025 as a first-line treatment for recurrent respiratory papillomatosis, represented not just a medical milestone but a test of whether scientific promise could translate into real-world adoption. On a Tuesday earnings call, the company's leadership gathered to account for that translation — to investors, to analysts, and in some sense, to themselves.
- Precigen crossed a threshold rare in biotech: an FDA approval that actually led to a commercial launch, with PAPZIMEOS entering the market as the first-line standard of care for adult RRP patients.
- The nine-month window between approval and this earnings call compressed years of commercial infrastructure-building — sales training, hospital negotiations, supply chain management — into a sprint with real stakes.
- Investors are watching whether regulatory success can become commercial durability, knowing that adoption by physicians, insurance coverage, and manufacturing reliability are each their own fragile chain.
- On the call, a full executive team — CEO, CFO, COO, and chief commercial officer — signaled that execution, not just science, is now the company's defining challenge.
- The trajectory is cautiously forward: progress is being reported, prescriptions are being written, and the question has shifted from 'will it be approved?' to 'will it be sustained?'
In May 2026, Precigen's leadership convened an earnings call to account for nine months of commercial life following a milestone years in the making. The previous August, the FDA had approved PAPZIMEOS — a treatment for recurrent respiratory papillomatosis, a condition in which benign tumors repeatedly obstruct the airways of adults — as a novel first-line standard of care. For Precigen, it was the company's first commercial therapeutic launch, and the call was a reckoning with how that launch was actually unfolding.
CEO Dr. Helen Sabzevari led the discussion, joined by her chief commercial officer, CFO, and COO — a full executive presence that underscored how much was riding on execution. The designation of PAPZIMEOS as a "first-line" treatment carried real clinical weight: it meant physicians would reach for this drug first, not as a fallback. But approval and adoption are different things, and the nine months since clearance had been spent on the unglamorous work of converting regulatory success into market reality — training sales teams, negotiating with hospital systems, and beginning to see actual prescriptions written.
What made the moment notable for investors was its rarity. Most biotech companies spend years in development only to face delay or rejection, and must rebuild momentum if approval eventually comes. Precigen had cleared that hurdle and entered the harder phase: sustained commercial execution in a specialized market where physicians needed to be educated, insurers needed to cover the drug, and patients needed access.
The call followed the familiar ritual of public company life — legal disclaimers, prepared remarks, analyst questions — but beneath the structure was a genuine inflection point. Nine months in, Precigen was no longer a company with a promising drug in trials. It was a company with a product in the market, generating revenue, and reporting to shareholders on whether that product could hold.
On a Tuesday afternoon in May, Precigen's leadership gathered on a conference call to walk investors through nine months of a milestone they'd been building toward for years. In August of the previous year, the FDA had cleared PAPZIMEOS, a drug designed to treat recurrent respiratory papillomatosis—a condition where benign tumors grow repeatedly in the throat and airways of adults. For Precigen, this wasn't just another approval. It was the company's first commercial therapeutic launch, and the executives on the call were there to report how that launch was unfolding in the real world.
Dr. Helen Sabzevari, the company's president and CEO, opened the discussion by framing what the approval meant: PAPZIMEOS had entered the market as a novel first-line standard of care for adult RRP patients. That language—"first-line"—carries weight in medicine. It means doctors would consider this drug first when treating the disease, not as a backup option. Joining Sabzevari on the call were Phil Tennant, the chief commercial officer tasked with getting the drug into hospitals and clinics; Harry Thomasian, the CFO watching the financial implications; and Raul Shah, the chief operating officer managing the machinery of execution.
The nine-month window between approval and this earnings call represented a compressed timeline for bringing a novel therapeutic to market. In that span, Precigen had moved from regulatory clearance to actual commercial operations—the unglamorous work of training sales representatives, negotiating with hospital systems, managing supply chains, and beginning to see real uptake from physicians and patients. The executives had come prepared with progress metrics, though the call transcript captures only the opening remarks before diving into the substance of what those nine months had yielded.
What made this moment significant for investors was the rarity of it. Most biotech companies spend years in development, face rejection or delay at the FDA, and then must rebuild momentum if approval finally comes. Precigen had cleared that hurdle and was now in the phase where execution mattered most—could they actually convert regulatory approval into sustained commercial success? The market for RRP treatment existed, but it was specialized. Doctors treating this condition needed to know about PAPZIMEOS, understand why it was better than existing options, and be willing to prescribe it. Patients needed access, insurance needed to cover it, and the company needed to manufacture it reliably.
The call itself was a standard ritual of public company life: leadership presenting prepared remarks, then fielding questions from analysts and investors who wanted to understand the trajectory. Steven Harasym, the VP of investor relations, had opened with the customary legal disclaimers—forward-looking statements carry risk, actual results may differ, review the SEC filings for details. It was boilerplate, but it reflected the reality that predicting the future of a newly launched drug is inherently uncertain. Manufacturing could stumble. Adoption could stall. Competitors could emerge. The market could shift.
But on this May afternoon, nine months in, Precigen was reporting progress. The company had moved from the theoretical—a drug that works in trials—to the actual: a drug in the market, being prescribed, generating revenue. What that progress looked like in concrete terms—how many patients had been treated, what revenue had been generated, what the sales pipeline looked like—would emerge in the detailed discussion that followed the opening remarks. For now, the frame was set: a company with its first commercial product, nine months into a launch, reporting to shareholders on how that launch was going.
Notable Quotes
The approval of PAPZIMEOS in August of 2025 has brought a novel first-line standard of care treatment for adults with RRP.— Dr. Helen Sabzevari, President and CEO
The Hearth Conversation Another angle on the story
Why does it matter that this is Precigen's first commercial launch? Couldn't any company launch a drug?
Because most biotech companies never get here. They spend a decade in labs and trials, burn through cash, and then the FDA says no. Precigen got the yes. Now they have to prove they can actually sell it, manufacture it, keep patients on it. That's a different skill set entirely.
So the nine months is the real test?
Exactly. The FDA approval was the permission slip. These nine months are the proof of concept—can they execute? Are doctors prescribing it? Are patients staying on it? Is the supply chain holding up?
What's the risk if they stumble now?
They've already spent the money to get here. If the commercial launch fails, they've got a cleared drug that isn't generating revenue. That's worse than not having a drug at all, because you've burned capital and have nothing to show for it.
Is RRP a big market?
It's specialized. Not huge, but real. Adults with this condition need treatment, and they need it repeatedly—the tumors come back. So it's not a one-time sale per patient. That's actually good for a company like Precigen.
What would success look like at this stage?
Steady adoption among ENT specialists, insurance companies covering it without too much friction, supply chain keeping up with demand, and revenue starting to climb. Nothing explosive, but consistent traction.